Page 62 - அமெரிக்கன் கால்நடை மருத்துவ சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ( Evvivax ), today announced the initiation of Phase I of a two-phase clinical trial to evaluate a LinearDNA COVID-19 vaccine candidate for the feline veterinary market. The goal of the trial is to evaluate the vaccine candidate as a strategy for the prevention of SARS-CoV-2, the virus that causes COVID-19, in feline companions of humans that may mitigate the animals as a potential reservoir for infections in humans. If successful, the clinical trial will also serve as an important initial validation of LinearDNA, Applied DNA s la

United statesJoseph impellizeriJamesa haywardLuigi aurisicchioUs department of agricultureSciences incDrug administrationVeterinary oncology services at guardian specialistsSecurities exchangeAmerican veterinary medical associationPlant health inspection serviceCandidate previously demonstrated antibodiesT cell responseMouse modelsInitial validationLarge mammals